Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.41 |
| ▸ | BCL2 | P10415 | 9/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935532 | 0.82 | MCL1 (0.54) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL2367500 | 0.80 | MCL1 (0.60) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14949237 | 0.75 | MCL1 (0.71) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14935299 | 0.72 | MCL1 (0.52) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14935375 | 0.68 | MCL1 (0.49) | MCL1BCL2BCL2L1FGFR1FLT1 | |
| SCHEMBL14935455 | 0.67 | BCL2 (0.48) | MCL1BCL2FGFR1FLT1FGFR3 | |
| SCHEMBL29523513 | 0.64 | MCL1 (0.78) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL14935359 | 0.64 | MCL1 (0.78) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367939 | 0.62 | MCL1 (0.88) | MCL1BCL2BCL2L1FGFR1 | |
| SCHEMBL2367447 | 0.62 | MCL1 (0.88) | MCL1BCL2BCL2L1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614333-B2 | Acenaphtho heterocyclic compound and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-12-24 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | MCL1, BCL2L1, BCL2 | MCL1 1/4885BCL2 3/4885BCL2L1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.